Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom, CuraGen Launch Drug Target Alliance

NEW YORK, March 13 - Sequenom and CuraGen will work together to probe disease-related genes by combining proteomics and population genetics, the companies said on Wednesday.

 

In the collaboration, Sequenom will identify genes relevant to disease through its population genetics approach, which applies whole-genome screens to discover relevant SNPs. CuraGen will apply proteomics techniques to characterize gene function, protein interaction and disease pathways, and thereby identify possible drug targets.

 

The companies did not discuss financial details of the agreement.

 

Sequenom has already identified more than 120 candidate genes, said company president and CEO Toni Schuh in a statement. CuraGen said its techniques will help validate these candidate genes, and ascertain which make the most viable targets for drug development.

 

As part of the partnership, CuraGen will also use Sequenom's SNP genotyping techniques to validate drug targets that it has already identfiied.

 

Sequenom, headquartered in San Diego, uses population genetics to identify common disease-related genes. It is a publicly owned company.

 

CuraGen, based in New Haven, Conn., uses functional genomics techniques to study genetic variations, gene expression, protein interactions, and potential drugs.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.